Latest Clinical Trials
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 The PROLONG Trial - Rituximab Maintenance Therapy in ITP Ostfold Hospital Trust NA COMPLETED
(Sep 1, 2026)
PHASE3 Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration Neurocrine UK Limited NA COMPLETED
(Sep 1, 2026)
PHASE1 A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects Neurocrine UK Limited NA COMPLETED
(Sep 1, 2026)
PHASE1 A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects Neurocrine UK Limited NA COMPLETED
(Sep 1, 2026)
PHASE1 Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy Neurocrine UK Limited NA WITHDRAWN
(Sep 1, 2026)
PHASE3 Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy University Hospital, Lille NA COMPLETED
(Sep 1, 2026)
PHASE3 Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Patients With Diabetic Macular Edema (LOADEX) Hospices Civils de Lyon NA COMPLETED
(Sep 1, 2026)
PHASE2 A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients Fondazione EMN Italy Onlus NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma University of Rochester NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma Genentech, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE1 Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma Emory University NA RECRUITING
(Sep 1, 2026)
PHASE2 Dexamethasone in Traumatic Brain Injury Assiut University NA RECRUITING
(Sep 1, 2026)
PHASE3 A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma Hoffmann-La Roche NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL Pfizer NA RECRUITING
(Sep 1, 2026)
PHASE2 Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2) Hospital General Universitario Gregorio Marañon NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) Jerry Lee, MD, MSc, MPhil NA RECRUITING
(Sep 1, 2026)
PHASE2 Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma Alliance for Clinical Trials in Oncology NA SUSPENDED
(Sep 1, 2026)
PHASE1, PHASE2 Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma University of Utah NA RECRUITING
(Sep 1, 2026)
PHASE2 EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema Eclipse Life Sciences, Inc. NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) AbbVie NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0) University of Miami NA RECRUITING
(Sep 1, 2026)
PHASE2 Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab Grupo Espanol de Tumores Neuroendocrinos NA TERMINATED
(Sep 1, 2026)
PHASE2 A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant AbbVie NA RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma CellCentric Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE2 Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) Sparrow Pharmaceuticals NA RECRUITING
(Sep 1, 2026)
PHASE2 Corticosteroid Lumbar Epidural Analgesia for Radicular Pain 2 Semnur Pharmaceuticals, Inc. NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp University of California, San Diego NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease Institute of Hematology & Blood Diseases Hospital, China NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Efficacy and Safety of Intracochlear Injection of Glucocorticoid Through the Round Window Membrane in Patients With Profound or Complete Sudden Sensorineural Hearing Loss Eye & ENT Hospital of Fudan University NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Randomized Controlled Trial Evaluating the Efficacy of Soaking Endotracheal Tube in Dexamethasone Solution for Prevention of Postoperative Sore Throat After Laparoscopic Cholecystectomy KRL Hospital, Islamabad NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma Hoffmann-La Roche NA RECRUITING
(Sep 1, 2026)
PHASE2 Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan Mario Negri Institute for Pharmacological Research NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months. Starship Child Health, Te Toka Tumai Auckland NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 The Effect of Dexamethasone on Short Term Patient Response: IV vs Oral Administration The University of Texas Health Science Center at San Antonio NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma National Cancer Institute (NCI) NA RECRUITING
(Aug 28, 2026)
PHASE2 Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NA RECRUITING
(Aug 27, 2026)
PHASE2 Ketoconazole Effects on the Daily Cortisol Rhythm in Mild Autonomous Cortisol Secretion National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NA RECRUITING
(Aug 27, 2026)
PHASE1 Co-analgesic Effects of Dexamethasone and Pregabalin After Lumbar Slipped Disc Surgery University Hospital, Clermont-Ferrand NA COMPLETED
(Aug 1, 2026)
PHASE3 Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients Fondazione Italiana Linfomi - ETS NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma Gustave Roussy, Cancer Campus, Grand Paris NA COMPLETED
(Aug 1, 2026)
PHASE3 Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver National Cancer Institute (NCI) NA COMPLETED
(Aug 1, 2026)
PHASE2 Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia National Cancer Institute (NCI) NA RECRUITING
(Aug 1, 2026)
PHASE2 Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL Dana-Farber Cancer Institute NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) NYU Langone Health NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery Memorial Sloan Kettering Cancer Center NA RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments Pfizer NA RECRUITING
(Aug 1, 2026)
PHASE3 A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL Huashan Hospital NA COMPLETED
(Aug 1, 2026)
PHASE1 A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma AbbVie NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM Sanofi NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment Janssen Research & Development, LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma Janssen Research & Development, LLC NA RECRUITING
(Aug 1, 2026)
PHASE3 A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant Pfizer NA RECRUITING
(Aug 1, 2026)
PHASE3 Premedication to Reduce Amivantamab Associated Infusion Related Reactions Janssen Research & Development, LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments GlaxoSmithKline NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma Cristiana Costa Chase, DO NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma Mayo Clinic NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma AstraZeneca NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma University of Heidelberg Medical Center NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking Maanasa Indaram, MD NA ENROLLING BY INVITATION
(Aug 1, 2026)
PHASE1, PHASE2 Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype Nantes University Hospital NA RECRUITING
(Aug 1, 2026)
PHASE3 Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. MedSIR NA RECRUITING
(Aug 1, 2026)
PHASE3 A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome Fayoum University NA COMPLETED
(Aug 1, 2026)
PHASE2, PHASE3 Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy University of Nebraska NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Corticosteroids Before Extubation in Pediatric Intensive Care Unit Assistance Publique - Hôpitaux de Paris NA RECRUITING
(Aug 1, 2026)
PHASE3 Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer Acerand Therapeutics (Hong Kong) Limited NA RECRUITING
(Aug 1, 2026)
PHASE1 A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) Fondazione Italiana Linfomi - ETS NA RECRUITING
(Aug 1, 2026)
PHASE2 Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC Swiss Cancer Institute NA RECRUITING
(Aug 1, 2026)
PHASE2 Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL Huashan Hospital NA RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma C4 Therapeutics, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE2 Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma Johns Hopkins All Children's Hospital NA RECRUITING
(Aug 1, 2026)
PHASE2 BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL Rong Tao NA RECRUITING
(Aug 1, 2026)
PHASE3 Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis Beijing Anzhen Hospital NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma Second Affiliated Hospital, Zhejiang University, School of Medicine NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL The First Affiliated Hospital of Xiamen University NA RECRUITING
(Aug 1, 2026)
PHASE2 GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma Fudan University NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Opioid-Free Anesthesia in Colorectal Surgery, 2025 (OFA-CRC-2025) Hospital Universitario La Fe NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI. Tianjin Medical University Cancer Institute and Hospital NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Early Corticosteroids in Severe Influenza Pneumonia Centre Hospitalier Régional Metz-Thionville NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma City of Hope Medical Center NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced Xerostomia University of California, Davis NA COMPLETED
(Aug 1, 2026)
PHASE1 Insulin Eye Drops and Epithelial Healing After Corneal Cross-linking Cairo University NA COMPLETED
(Aug 1, 2026)
PHASE2, PHASE3 Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis M.D. Anderson Cancer Center NA COMPLETED
(Jul 1, 2026)
PHASE1 Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma Celgene NA TERMINATED
(Jul 1, 2026)
PHASE1 Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Columbia University NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Immuno-PRISM (PRecision Intervention Smoldering Myeloma) Irene Ghobrial, MD NA RECRUITING
(Jul 1, 2026)
PHASE2 Elimination of Minimal Residual Disease After Transplant Medical College of Wisconsin NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia Ho Joon Im NA RECRUITING
(Jul 1, 2026)
PHASE2 A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery Oculis NA TERMINATED
(Jul 1, 2026)
PHASE3 A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients Hangzhou Sumgen Biotech Co., Ltd. NA RECRUITING
(Jul 1, 2026)
PHASE3 The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) Telix Pharmaceuticals (Innovations) Pty Limited NA RECRUITING
(Jul 1, 2026)
PHASE3 Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) Peking Union Medical College Hospital NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Outpatient Epcoritamab in Large B-cell Lymphoma Massachusetts General Hospital NA RECRUITING
(Jul 1, 2026)
PHASE2 Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors Tiago Biachi de Castria NA RECRUITING
(Jul 1, 2026)
PHASE2 Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases The Netherlands Cancer Institute NA RECRUITING
(Jul 1, 2026)
PHASE3 Comparative Efficacy of IV Dexamethasone vs. Nebulized Terbutaline for Renal Colic Pain in the ED University of Monastir NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) Mayo Clinic NA RECRUITING
(Jul 1, 2026)
PHASE3 A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations R-Pharm NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level University of Leeds NA RECRUITING
(Jul 1, 2026)
PHASE3 Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas Akshitkumar MIstry NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation Hematology department of the 920th hospital NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular Edema SANGMYUNG innovation NA RECRUITING
(Jul 1, 2026)
PHASE3 Chemical vs Mechanical Pleural Adhesiolysis for Liberation of Captive Pleura in Stacked Effusion Delta University for Science and Technology NA COMPLETED
(Jul 1, 2026)
PHASE2 A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) Biocad NA RECRUITING
(Jul 1, 2026)
PHASE3 Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. Polish Myeloma Consortium NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial) The Netherlands Cancer Institute NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer M.D. Anderson Cancer Center NA TERMINATED
(Jun 1, 2026)
PHASE1 Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone Alliance for Clinical Trials in Oncology NA TERMINATED
(Jun 1, 2026)
PHASE3 Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity Loma Linda University NA COMPLETED
(Jun 1, 2026)
PHASE3 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma ECOG-ACRIN Cancer Research Group NA RECRUITING
(Jun 1, 2026)
PHASE3 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types Eisai Inc. NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Sabine Mueller, MD, PhD NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Isatuximab in Combination With Novel Agents in RRMM - Master Protocol Sanofi NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT Mercator MedSystems, Inc. NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." Nantes University Hospital NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis CHA University NA COMPLETED
(Jun 1, 2026)
PHASE1, PHASE2 A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) Genentech, Inc. NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases Baptist Health South Florida NA SUSPENDED
(Jun 1, 2026)
PHASE1, PHASE2 Isa-Pom-Dex in Elderly/Frail Subjects With RRMM UNC Lineberger Comprehensive Cancer Center NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 BLOCK-SAH - PPF-Block for Post-SAH Headache University of Florida NA RECRUITING
(Jun 1, 2026)
PHASE2 PONV Prevention Via Percutaneous Nerve Electrical Stimulation on PC6 Peking Union Medical College Hospital NA COMPLETED
(Jun 1, 2026)
PHASE2 Effect of Intravenous Dexmedetomidine Versus Dexamethasone for Management of Repound Pain After Supraclavicular Brachial Plexus Block Assiut University NA COMPLETED
(Jun 1, 2026)
PHASE1 Anesthetic Block of the Erector Muscles of the Lumbar Spine to Relieve Acute Lumbar Pain: Pilot Study Elsan NA RECRUITING
(Jun 1, 2026)
PHASE3 Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma Mayo Clinic NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Sitagliptin in Recurrent/Progressive Grade 4 Glioma Kailin Yang, MD, PhD NA RECRUITING
(Jun 1, 2026)
PHASE1 Dexamethasone Treatment for Sepsis-associated Acute Respiratory Distress Syndrome: a Multicenter, Randomised, Double-blinded, Controlled Trial Southeast University, China NA RECRUITING
(Jun 1, 2026)
PHASE3 Midazolam Adjunct Therapy for Prevention of PONV in Gynecological Laparoscopy Hameed Latif Hospital, Lahore NA COMPLETED
(Jun 1, 2026)
PHASE2 Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL Liping Dou NA RECRUITING
(Jun 1, 2026)
PHASE1 Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of CINV in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis Sunnybrook Health Sciences Centre NA RECRUITING
(Jun 1, 2026)
PHASE2 Dexamethasone for Symptom Burden in Advanced Cancer Patients M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Massachusetts General Hospital NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting Celgene NA COMPLETED
(May 1, 2026)
PHASE2 Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer Fox Chase Cancer Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Dexamethasone in Controlling Dyspnea in Patients With Cancer M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant Ciusss de L'Est de l'Île de Montréal NA COMPLETED
(May 1, 2026)
PHASE2 Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma University Hospital, Caen NA TERMINATED
(May 1, 2026)
PHASE2 Evaluation of the Analgesia by Serratus Plane Block During Pleural Drainage in Intensive Care Unit. Centre Hospitalier Universitaire, Amiens NA RECRUITING
(May 1, 2026)
PHASE3 mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma OHSU Knight Cancer Institute NA TERMINATED
(May 1, 2026)
PHASE2 Combination of Ranibizumab and Targeted Laser Photocoagulation University of Giessen NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma City of Hope Medical Center NA RECRUITING
(May 1, 2026)
PHASE2 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma Emory University NA RECRUITING
(May 1, 2026)
PHASE2 Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma UNC Lineberger Comprehensive Cancer Center NA RECRUITING
(May 1, 2026)
PHASE2 Loncastuximab Tesirine in WM Shayna Sarosiek, MD NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. PETHEMA Foundation NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Dexamethasone Treatment for OSA in Children The Hospital for Sick Children NA COMPLETED
(May 1, 2026)
PHASE3 A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition Joseph Oved NA RECRUITING
(May 1, 2026)
PHASE2 Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma Universitätsklinikum Hamburg-Eppendorf NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) Merck Sharp & Dohme LLC NA COMPLETED
(May 1, 2026)
PHASE1, PHASE2 Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma Opna Bio LLC NA RECRUITING
(May 1, 2026)
PHASE1 Adjunctive Doxycycline for Central Nervous System Tuberculosis National University Hospital, Singapore NA RECRUITING
(May 1, 2026)
PHASE2 Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) SWOG Cancer Research Network NA RECRUITING
(May 1, 2026)
PHASE2, PHASE3 Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM GlaxoSmithKline NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM GlaxoSmithKline NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Soaked Pharyngeal Packing Agents in Septoplasty Assiut University NA COMPLETED
(May 1, 2026)
PHASE3 R-PMDT Regimen in Newly Diagnosed PCNSL Zou Dehui NA RECRUITING
(May 1, 2026)
PHASE2 Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas Allison Winter NA NOT YET RECRUITING
(May 1, 2026)
PHASE1 A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Wake Forest University Health Sciences NA NOT YET RECRUITING
(May 1, 2026)
PHASE1 Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification Institute of Hematology & Blood Diseases Hospital, China NA NOT YET RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers Dipnarine Maharaj NA ENROLLING BY INVITATION
(Apr 1, 2026)
PHASE1, PHASE2 Dexmedetomidine Intra Venous Arthroplasty CMC Ambroise Paré NA COMPLETED
(Apr 1, 2026)
PHASE3 International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma University Hospital Muenster NA RECRUITING
(Apr 1, 2026)
PHASE3 Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) GlaxoSmithKline NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Mats Heyman NA RECRUITING
(Apr 1, 2026)
PHASE3 Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis St. Jude Children's Research Hospital NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases M.D. Anderson Cancer Center NA RECRUITING
(Apr 1, 2026)
PHASE2 A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) Oculis NA COMPLETED
(Apr 1, 2026)
PHASE2, PHASE3 Opioid Free Anesthesia in Total Hip Arthroplasty CMC Ambroise Paré NA COMPLETED
(Apr 1, 2026)
PHASE3 Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants Region Skane NA COMPLETED
(Apr 1, 2026)
PHASE1 Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL Institute of Hematology & Blood Diseases Hospital, China NA RECRUITING
(Apr 1, 2026)
PHASE1 Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone Immune Oncology Research Institute NA COMPLETED
(Apr 1, 2026)
PHASE3 Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma SCRI Development Innovations, LLC NA RECRUITING
(Apr 1, 2026)
PHASE2 Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies Abdullah Khan NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Treating Respiratory Emergencies in Children Study Oregon Health and Science University NA COMPLETED
(Apr 1, 2026)
PHASE2 A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) Oculis NA COMPLETED
(Apr 1, 2026)
PHASE3 Parasitic Ulcer Treatment Trial Jeremy Keenan, MD, MPH NA RECRUITING
(Apr 1, 2026)
PHASE3 Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma Fudan University NA RECRUITING
(Apr 1, 2026)
PHASE2 NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens Fudan University NA COMPLETED
(Apr 1, 2026)
PHASE3 Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. Laboratorios Sophia S.A de C.V. NA COMPLETED
(Apr 1, 2026)
PHASE1 Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss Seoul National University Hospital NA WITHDRAWN
(Apr 1, 2026)
PHASE1, PHASE2 Open-Label Extension of EryDex Study IEDAT-04-2022 Quince Therapeutics S.p.A. NA TERMINATED
(Apr 1, 2026)
PHASE3 A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) GlaxoSmithKline NA RECRUITING
(Apr 1, 2026)
PHASE3 Comparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures Nishtar Medical University NA RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects C4 Therapeutics, Inc. NA RECRUITING
(Apr 1, 2026)
PHASE1 Trans-round Window Membrane Intracochlear Steroid Eye & ENT Hospital of Fudan University NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases: The Second Affiliated Hospital of Hainan Medical University NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Improvement Effect of Dexamethasone Enema for Acute Radiation-induced Rectal Injury Sixth Affiliated Hospital, Sun Yat-sen University NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia Shandong University NA RECRUITING
(Apr 1, 2026)
PHASE3 QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms Qilu Pharmaceutical Co., Ltd. NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Dexamethasone in Tick-borne Encephalitis University Medical Centre Ljubljana NA RECRUITING
(Apr 1, 2026)
PHASE3 Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma Janssen Research & Development, LLC NA COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer Centre Oscar Lambret NA TERMINATED
(Mar 1, 2026)
PHASE2 Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma C4 Therapeutics, Inc. NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Medical College of Wisconsin NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) Merck Sharp & Dohme LLC NA COMPLETED
(Mar 1, 2026)
PHASE1 Evaluate the Neurological Effects of EryDex on Subjects With A-T Quince Therapeutics S.p.A. NA COMPLETED
(Mar 1, 2026)
PHASE3 A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) University of Chicago NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Alfred Chung, MD NA RECRUITING
(Mar 1, 2026)
PHASE1 Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy The First Affiliated Hospital of Soochow University NA RECRUITING
(Mar 1, 2026)
PHASE2 Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss The Affiliated Hospital of Qingdao University NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study Zhejiang Cancer Hospital NA COMPLETED
(Mar 1, 2026)
PHASE2 Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis Assistance Publique - Hôpitaux de Paris NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE3 Comparative Effectiveness of Clindamycin-Retinoid, Clindamycin-Retinoid-Dexamethasone, and 10% SM-hUCMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgaris Yohanes Firmansyah, dr, MH, MM NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 
